Exosome Therapies Market Poised for Significant Growth Through 2036 as Expanding Target Populations and Biopharma Innovation Create New Opportunities

Exosome therapies offer broad regenerative and targeted-delivery potential, while standardization, scalability and regulatory hurdles create key innovation opportunities.

Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Exosome Therapies - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The "Exosome Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report provides a comprehensive assessment of the exosome therapies market across the United States, EU4 countries (Germany, France, Italy and Spain), the United Kingdom and Japan. Covering the period from 2022 to 2036, the report evaluates market trends, addressable patient populations, emerging therapies, clinical development, competitive positioning, market access and future commercial opportunities.

Key Market Highlights

• Exosome therapy development continues to face regulatory and manufacturing challenges, including limited standardization in production, product characterization and quality control. Variability in exosome composition, scalability constraints and evolving regulatory requirements have restricted late-stage development. No exosome-based therapy has received full regulatory approval in major markets despite increasing clinical and commercial interest.
• Exosome therapeutics remain a promising Next -generation biologic platform across regenerative medicine, oncology, neurological disorders, inflammatory diseases and rare conditions. Innovation is centered on regenerative and immunomodulatory applications, as well as engineered exosomes for targeted delivery of proteins, nucleic acids and gene-editing payloads.
• Key clinical candidates include DB-2Q from Direct Biologics, AGLE-102 from Aegle Therapeutics and BRE-AD01 from BREXOGEN. Their clinical progress is expected to influence the future exosome therapies competitive landscape and market outlook.

Exosome Therapies Market Analysis

The report examines historical and forecasted exosome therapies market size, market share by therapy and indication, treatment practices, eligible patient populations and anticipated drug uptake across the seven major markets. It also assesses unmet medical needs, treatment accessibility, physician adoption, patient acceptance, pricing and reimbursement considerations.

Commercial performance will depend on clinical safety and efficacy, manufacturing consistency, regulatory outcomes, treatment costs, launch sequencing and differentiation from established therapies. The report compares emerging candidates using available clinical data, trial design, enrollment, inclusion criteria and development stage. It also reviews early-stage companies and technologies that may shape the exosome therapies pipeline through 2036.

Target Patient Population and Epidemiology

• Atopic dermatitis affects up to 20% of children and approximately 10% of adults worldwide, according to published research cited in the report. Prevalence in the United States is estimated at 7.3%, supporting significant development potential for therapies addressing chronic inflammatory skin disease.
• The World Health Organization's Global Burden of Disease initiative estimates that more than 230 million people worldwide have atopic dermatitis. Skin diseases collectively rank as the fourth-leading cause of non-fatal disability globally.
• The National Organization for Rare Disorders reported in 2025 that Duchenne muscular dystrophy has an estimated birth prevalence of one in every 3,500 live male births in the United States.
• Published epidemiological estimates indicate that Japan records approximately 28,000 cases of acute respiratory distress syndrome annually, demonstrating the continued need for effective therapeutic interventions.

Emerging Exosome Therapies

DB-2Q: Direct Biologics

DB-2Q is a mesenchymal stromal cell-derived exosome candidate under investigation for inflammatory and respiratory disorders. Its development program is focused on immune modulation, inflammation reduction and tissue repair. The candidate is reported to be in Phase III clinical development.

AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle therapy in Phase I/II development for inflammatory and regenerative indications. Aegle Therapeutics is evaluating the candidate in recessive dystrophic epidermolysis bullosa and other disease settings associated with inflammation and impaired healing.

In July 2025, Aegle Therapeutics appointed Scott Braunstein, M.D., as Chairman of its Board of Directors. In March 2025, the company highlighted AGLE-102 as a first-in-class extracellular vesicle therapy and confirmed the continuation of its Phase I/IIa clinical evaluation in patients with recessive dystrophic epidermolysis bullosa.

BRE-AD01: BREXOGEN

BRE-AD01 is an adipose tissue-derived exosome candidate in Phase I development for atopic dermatitis. The program is designed to address inflammation, skin barrier dysfunction and clinical symptoms associated with moderate-to-severe disease.

In May 2026, BREXOGEN reported interim Phase I findings at the Society for Investigative Dermatology 2026 Annual Meeting. A single subcutaneous dose demonstrated favorable safety and tolerability, with statistically significant improvements in Eczema Area and Severity Index, Investigator's Global Assessment and body surface area measurements through Week 8. In March 2026, the company also presented first-in-human data at EAACI 2026 showing durable clinical improvements through Week 8.

Recent Market Developments

In July 2026, an FDA advisory committee voted 9-3 against the efficacy evidence submitted for deramiocel (CAP-1002) in Duchenne muscular dystrophy-associated cardiomyopathy. The FDA's Biologics License Application decision was expected by August 22, 2026. In May 2026, Capricor Therapeutics initiated legal Action against Nippon Shinyaku concerning United States commercialization rights. The report considers relevant developments across advanced biologic platforms where they may affect investment, regulation and competitive strategy in the broader extracellular vesicle and regenerative medicine sectors.

Pipeline, Competition and Drug Uptake

The exosome therapies pipeline analysis covers Phase II and Phase III candidates, clinical trial activity, mechanisms of Action , collaborations, licensing agreements, mergers and acquisitions, patents and anticipated approval timelines. Drug uptake forecasts consider competitive differentiation, available safety and efficacy data, regulatory positioning, launch order and physician confidence.

Developers conducting pivotal and confirmatory trials must select appropriate comparators and generate evidence that satisfies regulatory and health technology assessment requirements. Manufacturing reproducibility, scalable production and validated quality standards will remain critical to approval, commercialization and adoption.

Market Access and Reimbursement

The report assesses health technology assessment, pricing and reimbursement frameworks across the 7MM, including recent policy reforms and their potential effects on advanced biologic therapies. In the United States, the multipayer pricing environment continues to evolve following federal measures introduced under the Inflation Reduction Act. Germany follows a distinct launch and reimbursement pathway in which a new therapy may enter the market before completion of subsequent Benefit assessment and price negotiation procedures.

Coverage also includes potential reimbursement pathways for approved therapies, future access barriers, geographic pricing differences, patient assistance considerations and the affordability challenges associated with complex biologic products.

Expert and Qualitative Analysis

Primary research incorporates perspectives from more than 25 key opinion leaders, including physicians, therapeutic-area researchers and industry experts. These insights address the role of exosome therapies in evolving treatment pathways, reliance on conventional treatments, willingness to switch therapies, expected adoption and barriers to accessibility.

Qualitative analysis includes SWOT assessments and analyst perspectives covering diagnosis, patient awareness, competition, cost-effectiveness, geographic access, treatment preferences and unmet needs. These findings support strategic planning for clinical development, market entry and commercialization.

Report Scope and Key Strengths

• Exosome therapies market forecasts through 2036 across the United States, EU4, the United Kingdom and Japan.
• Historical and forecasted market size by therapy and indication.
• Total Fina Elf addressable patient populations and indication-level epidemiology.
• Competitive analysis of current and emerging exosome therapy candidates.
• Clinical pipeline profiles, drug uptake forecasts and key market assumptions.
• Patient journey, biomarker testing, physician perspectives and treatment preferences.
• SWOT analysis, analyst views, unmet needs and future market opportunities.
• Market access, reimbursement, pricing and geographic accessibility insights.
• Coverage of collaborations, licensing, acquisitions, mergers and patent activity.

Reasons to Buy

The report supports pharmaceutical companies, biotechnology developers, investors and other stakeholders seeking to understand the exosome therapies market. It helps organizations identify emerging competitors, evaluate clinical and commercial opportunities, assess Target patient populations and develop evidence-based market entry strategies.

Readers can use the analysis to evaluate market drivers and barriers, compare pipeline assets, understand regional access requirements and anticipate factors affecting approval and uptake. The report also provides insights into physician expectations, patient acceptance, pricing variation and the limitations of existing treatment options.

Key Questions Addressed

• How will the exosome therapies market size and therapy-level market shares change through 2036?
• Which clinical candidates and indications are likely to drive future market growth?
• How will manufacturing, regulatory and quality-control challenges affect commercialization?
• What are the market access and reimbursement scenarios across the 7MM?
• How do pricing, accessibility and treatment acceptance vary by geography?
• Which emerging technologies may address the limitations of current therapies?
• What factors will influence physician adoption, patient acceptance and drug uptake?

With extensive coverage of the exosome therapies pipeline, Target patient populations, competitive landscape and 7MM market forecasts, the report provides a strategic resource for assessing opportunities in one of the most closely watched areas of Next -generation biologic development.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Exosome Therapies

4. Key Events

5. Exosome Therapies Market Overview At A Glance
5.1. Market Share (%) Distribution of Exosome Therapies By Therapy in 2025
5.2. Market Share (%) Distribution of Exosome Therapies By Therapy in 2036

6. Background And Overview

7. Target Population

8. Exosome Therapies Marketed Drugs
8.1. Key Competitors
8.2. Company 1: Product 1
8.2.1. Product Description
8.2.2. Regulatory Milestones
8.2.3. Other Developmental Activities
8.2.4. Ongoing Clinical Development
8.2.5. Safety and Efficacy
8.3. Company 2: Product 2
8.3.1. Product Description
8.3.2. Regulatory Milestones
8.3.3. Other Developmental Activities
8.3.4. Ongoing Clinical Development
8.3.5. Safety and Efficacy
List to be continued.

9. Exosome Therapies Emerging Drugs
9.1. Key Competitors
9.2. Company 1: Product 1
9.2.1. Product Description
9.2.2. Other Development Activities
9.2.3. Clinical Development
9.2.3.1. Clinical Trials Information
9.2.4. Safety and Efficacy
9.3. Company 2: Product 2
9.3.1. Product Description
9.3.2. Other Development Activities
9.3.3. Clinical Development
9.3.3.1. Clinical Trials Information
9.3.4. Safety and Efficacy
List to be continued.

10. Exosome Therapies: The 7MM Analysis
10.1. Key Findings
10.2. Market Outlook
10.3. Key Market Forecast Assumptions
10.4. Total Fina Elf Market Size of Exosome Therapies in the 7MM
10.4.1. Market Size of Exosome Therapies By Therapies In the 7MM
10.4.2. Market Size of Exosome Therapies By Indication In the 7MM
10.6. United States Market
10.6.1. Total Fina Elf Market Size of Exosome Therapies in the United States
10.6.2. Market Size of Exosome Therapies By Therapies in the United States
10.7. EU4 and the UK Market
10.7.1. Total Fina Elf Market Size of Exosome Therapies in EU4 and the UK
10.7.2. Market Size of Exosome Therapies By Therapies in EU4 and the UK
10.8. Japan Market
10.8.1. Total Fina Elf Market Size of Exosome Therapies in Japan
10.8.2. Market Size of Exosome Therapies By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement
14.1. United States
14.1.1. Centre for Medicare & Medicaid Services (CMS)
14.2. EU4 and the UK
14.2.1. Germany
14.2.2. France
14.2.3. Italy
14.2.4. Spain
14.2.5. United Kingdom
14.3. Japan
14.3.1. MHLW

15. Appendix
15.1. Bibliography
15.2. Report Methodology

16. Analyst's Capabilities

17. Disclaimer

18. About the Publisher

List of Tables
Table 1: Target Population in the 7MM (2022-2036)
Table 2: Marketed Drug Key cross
Table 3: Product 1, Clinical Trial Description, 2025
Table 4: Product 2, Clinical Trial Description, 2025
Table 5: Emerging Drug Key cross
Table 6: Product 1, Clinical Trial Description, 2025
Table 7: Product 2, Clinical Trial Description, 2025
Table 8: Total Fina Elf Exosome Therapies Market Size in the 7MM (2022-2036)
Table 9: Exosome Therapies Market Size by Therapies in the 7MM (2022-2036)
Table 10: Exosome Therapies Market Size by Indication in the 7MM (2022-2036)
Table 11: Total Fina Elf Exosome Therapies Market Size in the United States (2022-2036)
Table 12: Exosome Therapies Market Size by Therapies in the United States (2022-2036)
Table 13: Total Fina Elf Exosome Therapies Market Size in EU4 and the UK (2022-2036)
Table 14: Exosome Therapies Market Size by Therapies in EU4 and the UK (2022-2036)
Table 15: Total Fina Elf Exosome Therapies Market Size in Japan (2022-2036)
Table 16: Exosome Therapies Market Size by Therapies in Japan (2022-2036)

List of Figures
Figure 1: Target Population in the 7MM (2022-2036)
Figure 2: Total Fina Elf Exosome Therapies Market Size in the 7MM (2022-2036)
Figure 3: Exosome Therapies Market Size by Therapies in the 7MM (2022-2036)
Figure 4: Exosome Therapies Market Size by Indication in the 7MM (2022-2036)
Figure 5: Total Fina Elf Exosome Therapies Market Size in the United States (2022-2036)
Figure 6: Exosome Therapies Market Size by Therapies in the United States (2022-2036)
Figure 7: Total Fina Elf Exosome Therapies Market Size in EU4 and the UK (2022-2036)
Figure 8: Exosome Therapies Market Size by Therapies in EU4 and the UK (2022-2036)
Figure 9: Total Fina Elf Exosome Therapies Market Size in Japan (2022-2036)
Figure 10: Exosome Therapies Market Size by Therapies in Japan (2022-2036)

A selection of companies mentioned in this report includes, but is not limited to:

• Direct Biologics
• Aegle Therapeutics
• BREXOGEN

For more information about this report visit https://www.researchandmarkets.com/r/xa72kr

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900